<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives"><meta name="DC.contributor" content="Ki Whan Hong" scheme="inventor"><meta name="DC.contributor" content="Otsuka Pharmaceutical Company, Limited" scheme="assignee"><meta name="DC.date" content="2003-4-23" scheme="dateSubmitted"><meta name="DC.description" content="A new active oxygen scavenger which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl group, A is lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, and an agent for the prevention or treatment of an acute cerebral infarction comprising the same active ingredient."><meta name="DC.date" content="2004-6-1" scheme="issued"><meta name="DC.relation" content="JP:S5649378" scheme="references"><meta name="DC.relation" content="US:4277479" scheme="references"><meta name="citation_reference" content="Jae Moon Choi et al., &quot;Neuroprotective Effect of Cilostazol Against Focal Cerbral Ischemia via Antipoptotic Action in Rats,&quot; The Journal of Pharmacology and Experimental Therapeutics, vol. 300, No. 3, pp. 787-793, (2002)."><meta name="citation_reference" content="Koizumi et al., :Changes in platelet aggregability, etc. CA 132:1611050, dtd. 2000."><meta name="citation_reference" content="Lee et al., &quot;Neuroprotective Effect of Cilostazol Against Focal Ischemic Brain Damage,&quot; Program &amp; Abstracts, The Korean Society of Pharmacology, p. 148, P 016, (11/5/01)."><meta name="citation_reference" content="Lee et al., &quot;Neuroprotective Effect of Cilostazol Against Focal Ischemic Brain Damage,&quot; The Korean Journal of Physiology &amp; Pharmacology, vol. 5., No. 6, Supplement, P-016, (12/01)."><meta name="citation_reference" content="Nagai, &quot;TNF-.alpha. formation inhibitors, etc.&quot; CA 129:76497, dtd. 1998."><meta name="citation_reference" content="Nishi et al. IV, &quot;Research and development, etc.&quot; CA 134:187764, dtd. 2001."><meta name="citation_reference" content="Nishi et al.., &quot;Studies on 2-oxoquinoline, etc.&quot; CA 99:98806, dtd. 1983."><meta name="citation_reference" content="Oishi et al., &quot;Effect of cilostazol, etc.&quot; CA 133:12525, dated 2000."><meta name="citation_reference" content="Otsuka, Carbostyril derivatives, etc., CA 95:126250, dtd, 1981."><meta name="citation_reference" content="Shinoda-Tagawa et al., &quot;A phosphodiesterase inhibitor, etc.&quot; CA 137:288846, dtd. 2002."><meta name="citation_reference" content="Watanabe et al., &quot;Effect of cilostazol on, etc.&quot; CA 105:91040, dtd. 1986."><meta name="citation_patent_number" content="US:6743806"><meta name="citation_patent_application_number" content="US:10/420,742"><link rel="canonical" href="http://www.google.com/patents/US6743806"/><meta property="og:url" content="http://www.google.com/patents/US6743806"/><meta name="title" content="Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives"/><meta name="description" content="A new active oxygen scavenger which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl group, A is lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, and an agent for the prevention or treatment of an acute cerebral infarction comprising the same active ingredient."/><meta property="og:title" content="Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("sKjtU97pHeunsATggIHgAg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NOR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("sKjtU97pHeunsATggIHgAg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NOR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6743806?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6743806"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=9aVmBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6743806&amp;usg=AFQjCNGQdmU53i-KZBSLJ8r4Rnryek8c_A" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6743806.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6743806.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20040082608"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US6743806"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6743806" style="display:none"><span itemprop="description">A new active oxygen scavenger which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl group, A is lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt...</span><span itemprop="url">http://www.google.com/patents/US6743806?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives" title="Patent US6743806 - Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6743806 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/420,742</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jun 1, 2004</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 23, 2003</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Oct 23, 2002</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US20040082608">US20040082608</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10420742, </span><span class="patent-bibdata-value">420742, </span><span class="patent-bibdata-value">US 6743806 B2, </span><span class="patent-bibdata-value">US 6743806B2, </span><span class="patent-bibdata-value">US-B2-6743806, </span><span class="patent-bibdata-value">US6743806 B2, </span><span class="patent-bibdata-value">US6743806B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Ki+Whan+Hong%22">Ki Whan Hong</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Otsuka+Pharmaceutical+Company,+Limited%22">Otsuka Pharmaceutical Company, Limited</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6743806.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6743806.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6743806.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (2),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (11),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (6),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (7),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6743806&usg=AFQjCNEyOgiTIXgxg1tmLM-ZfQl4BgbY6g">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6743806&usg=AFQjCNGENBO73WvROeit0eenORo772PlcA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6743806B2%26KC%3DB2%26FT%3DD&usg=AFQjCNF0C7ok_LlPHhKe9RLLcZU2jK-0cQ">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129198628" lang="EN" load-source="ifi">Tetrazolylalkoxy-dihydrocarbostyril compound; treatment of an acute cerebral infarction; 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-substituted-2-quinolinone derivatives</invention-title></span><br><span class="patent-number">US 6743806 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50674788" lang="EN" load-source="patent-office"> <div class="abstract">A new active oxygen scavenger which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00001.png"> <img id="EMI-C00001" file="US06743806-20040601-C00001.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00001" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00001.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00001" attachment-type="cdx" file="US06743806-20040601-C00001.CDX"> </attachment> <attachment idref="CHEMMOL-00001" attachment-type="mol" file="US06743806-20040601-C00001.MOL"> </attachment> </attachments> </chemistry> </div>
    <div class="abstract">wherein R is cycloalkyl group, A is lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, and an agent for the prevention or treatment of an acute cerebral infarction comprising the same active ingredient.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(2)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6743806B2/US06743806-20040601-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6743806B2/US06743806-20040601-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(8)</span></span></div><div class="patent-text"><div mxw-id="PCLM8681467" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6743806-B2-CLM-00001" class="claim">
      <div class="claim-text">1. A method of scavenging an active oxygen, which comprises administering to a subject in need thereof an effective amount of a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00003.png"> <img id="EMI-C00003" file="US06743806-20040601-C00003.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00003" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00003.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00003" attachment-type="cdx" file="US06743806-20040601-C00003.CDX"> </attachment> <attachment idref="CHEMMOL-00003" attachment-type="mol" file="US06743806-20040601-C00003.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is a single bond or a double bond, or a pharmaceutically acceptable salt of said compound.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6743806-B2-CLM-00002" class="claim">
      <div class="claim-text">2. The method according to <claim-ref idref="US-6743806-B2-CLM-00001">claim 1</claim-ref>, wherein the tetrazolylalkoxy-dihydrocarbostyril compound (I) is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim"> <div num="3" id="US-6743806-B2-CLM-00003" class="claim">
      <div class="claim-text">3. A method of scavenging a hydroxyl radical, which comprises administering to a subject in need thereof an effective amount of a tetrazolylalkoxy-dihydrocarbostyril compound <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00004.png"> <img id="EMI-C00004" file="US06743806-20040601-C00004.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00004" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00004.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00004" attachment-type="cdx" file="US06743806-20040601-C00004.CDX"> </attachment> <attachment idref="CHEMMOL-00004" attachment-type="mol" file="US06743806-20040601-C00004.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is a single bond or a double bond, or a pharmaceutically acceptable salt of said compound.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" id="US-6743806-B2-CLM-00004" class="claim">
      <div class="claim-text">4. The method according to <claim-ref idref="US-6743806-B2-CLM-00003">claim 3</claim-ref>, wherein the tetrazolylalkoxy-dihydrocarbostyril compound (I) is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]3,4-dihydrocarbostyril or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim"> <div num="5" id="US-6743806-B2-CLM-00005" class="claim">
      <div class="claim-text">5. A method for the treatment of injuries and diseases induced by excess generation of active oxygen species, which comprises administering to a subject in need of such treatment an effective amount of a tetrazolylalkoxy-dihydrocarbostyril compound <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00005.png"> <img id="EMI-C00005" file="US06743806-20040601-C00005.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00005" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00005.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00005" attachment-type="cdx" file="US06743806-20040601-C00005.CDX"> </attachment> <attachment idref="CHEMMOL-00005" attachment-type="mol" file="US06743806-20040601-C00005.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is a single bond or a double bond, or a pharmaceutically acceptable salt of said compound.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6743806-B2-CLM-00006" class="claim">
      <div class="claim-text">6. The method according to <claim-ref idref="US-6743806-B2-CLM-00005">claim 5</claim-ref>, wherein the tetrazolylalkoxy-dihydrocarbostyril compound (I) is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim"> <div num="7" id="US-6743806-B2-CLM-00007" class="claim">
      <div class="claim-text">7. A method for the treatment of injuries of reperfusion in the organs, the liver or renal dysfunction induced by transplantation or microcirculation dysfunction, epilepsy, acute cerebral infarction, or disorders due to abnormal generation of active oxygen induced by any cause other than ischemia, which comprises administering to a subject in need of such treatment an effective amount of a tetrazolylalkoxy-dihydrocarbostyril compound <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00006.png"> <img id="EMI-C00006" file="US06743806-20040601-C00006.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00006" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00006.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00006" attachment-type="cdx" file="US06743806-20040601-C00006.CDX"> </attachment> <attachment idref="CHEMMOL-00006" attachment-type="mol" file="US06743806-20040601-C00006.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is a single bond or a double bond, or a pharmaceutically acceptable salt of said compound.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" id="US-6743806-B2-CLM-00008" class="claim">
      <div class="claim-text">8. The method according to <claim-ref idref="US-6743806-B2-CLM-00007">claim 7</claim-ref>, wherein the tetrazolylalkoxy-dihydrocarbostyril compound (I) is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a pharmaceutically acceptable salt thereof.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54189190" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATION</heading> <p>This application is a divisional of application Ser. No. 10/278,074, filed Oct. 23, 2002 now abandoned which is incorporated by reference.</p>
    <heading>TECHNICAL FIELD</heading> <p>The present invention relates to a new active oxygen scavenger. More particularly, it relates to an active oxygen scavenger comprising as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00002.png"> <img id="EMI-C00002" file="US06743806-20040601-C00002.TIF" wi="161.5383" he="100.33065" img-content="chem" img-format="tif" alt="Figure US06743806-20040601-C00002" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-C00002.png" class="patent-full-image" width="646" height="401"> </a> </div> <attachments> <attachment idref="CHEMCDX-00002" attachment-type="cdx" file="US06743806-20040601-C00002.CDX"> </attachment> <attachment idref="CHEMMOL-00002" attachment-type="mol" file="US06743806-20040601-C00002.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus means a single bond or a double bond, or a salt thereof, and an agent for the prevention or treatment of an acute cerebral infarction.</p>
    <heading>TECHNICAL BACKGROUND</heading> <p>Oxygen is essential for a living body in order to maintain life, for example, to keep normal energy production and metabolism. The oxygen may be changed into so-called active oxygen species such as an oxygen anion radical, a peroxyl radical, a hydroxyl radical by reactions in the energy producing system, an oxygen reaction, a reaction with ultraviolet or X-ray, etc. The active oxygen species are useful for living body, e.g. for oxygen-addition enzyme or antibacterial action of leukocytes, but on the other hand, the species promote peroxidation of unsaturated fatty acids such as oleic acid, linolenic acid, or arachidonic acid which form phospholipids in living membranes. The lipid peroxides induce generation of alkoxy radicals and hydroxyl radicals like the above active oxygen species, and attack the living membranes which results in membrane injury or inactivation of various enzymes. (cf. “TAISHA (Metabolism)” 15(10), 1978, “Special Feature of Active Oxygen”) However, the living body includes various enzymes such as superoxide dimutase (SOD), catalase, glutathione peroxidase, which participate in metabolic inactivation of active oxygen species as mentioned above, and also includes vitamins such as α-tocopherol (vitamin E) which have an antioxidation activity. The living body is usually maintained in normal state by the actions of these enzymes and vitamins. However, there may happen deficiency in the biophylactic mechanism by these enzymes and vitamins or excess generation of active oxygen species which induce loss of control of the biophylactic mechanism or production and deposition of lipid peroxides. When deficiency of biophylactic mechanism occurs, peroxidation reactions will progress into chain reaction, which induce serious disorders, for example acute cerebral infarction.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The present inventors have intensively studied to develop a new medicament for scavenging active oxygen and found that the carbostyril compound of the formula (I) or a salt thereof as mentioned above, particularly 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof, have an activity of scavenging active oxygen species and hence are useful as an active oxygen scavenger, and then the present invention has been accomplished.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p>FIG. 1 shows an electron paramagnetic resonance (EPR) spectra of the spin-adduct of 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) with the hydroxyl radical:</p>
    <p>DMPO/.OH showing effect of cilostazol (tradename of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril) on acavenging of hydroxyl radical.</p>
    <p>FIG. 2 shows the time-dependent decrease of β-phycoerythrin fluorescence in the absence (blank) and the presence of different concentrations of cilostazol, which shows peroxyradical absorbing capacity of cilostazol.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>The present invention provides a new active oxygen scavenger comprising as an active ingredient a tetrazolyl-alkoxy-carbostyril alkoxy-carbostyril compound of the formula (I) or a salt thereof.</p>
    <p>The compound of the formula (I) or a salt thereof has excellent active oxygen scavenging effect and hence can inhibit the production of lipid peroxides. Thus, the active oxygen scavenger of the present invention comprising as an active ingredient the compound of the formula (I) or a salt thereof is useful for the prevention and treatment of various injuries and diseases induced by excess generation of active oxygen species, deposition of lipid peroxides or loss of biophylactic mechanism against them. Particularly, the compound of the present invention has very potent activity of scavenging hydroxyl radical having the highest toxicity to tissue among the active oxygen species and can scavenge also peroxyl radical.</p>
    <p>More specifically, the active oxygen scavenger of the present invention is useful as a medicament for the prevention the cells in various tissues from injuries associated with ischemia, particularly reperfusion, and hence is useful for the prevention or treatment of injuries of reperfusion in the organs; the liver/renal dysfunction induced by transplantation or microcirculation dysfunction; epilepsy; acute cerebral infarction; or various disorders due to abnormal generation of active oxygen induced by any cause other than ischemia, for example arthritis.</p>
    <p>The tetrazolylalkoxy-dihydrocarbostyril compounds of the formula (I) and processes for preparation thereof are disclosed in JP-63-20235.</p>
    <p>In the formula (I), the “cycloalkyl group” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. but preferable one is cyclohexyl. The “lower alkylene group” includes methylene, ethylene, propylene, butylene, etc. but preferable one is butylene.</p>
    <p>Particularly preferred compound is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, which has been sold as a vasodilator under a tradename of cilostazol.</p>
    <p>The compound of the formula (I) of the, present invention can be used in bulk or preferably in the form of a pharmaceutical preparation with a conventional pharmaceutical carrier or diluent. The dosage form is not limited to a specific form, but may be in any conventional dosage forms, for example, preparations for oral administration, such as tablets, capsules, granules, various liquid preparations suitable for oral administration, or preparations for parenteral administration, such as injections, suppositories. For prevention or treatment of acute cerebral infarction, it is preferable to use in the form of an injection. The dosage is not limited to a specific range but is usually in the range of 100 to 400 mg per day in adult (50 kg of body weight) which is administered once or being divided in one to several times. The active compound is preferably contained in the preparation in an amount of 50 to 100 mg per dosage unit.</p>
    <p>The preparation for injection is usually prepared in the form of a liquid preparation, an emulsion, or a suspension, which are sterilized and further are preferably made isotonic to the blood. The preparations in the form of a liquid, emulsion or suspension are usually prepared by using conventional pharmaceutical diluents, for example, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters. These preparations may be incorporated with an isotonic agent such as sodium chloride, glucose, glycerin in an amount sufficient for making isotonic and may further incorporated with conventional solubilizers, buffers, anesthetizing agents, and optionally colorants, preservatives, fragrant materials, flavors, sweetening agents, and other medicaments.</p>
    <p>The preparations such as tablets, capsules, liquid for oral administration may be prepared by a conventional method. The tablets may be prepared by mixing with conventional pharmaceutical carriers such as gelatin, starches, lactose, magnesium stearate, talc, gum arabic, and the like. The capsules may be prepared by mixing with inert pharmaceutical fillers or diluents and filled in a hard gelatin capsule or a soft capsule. The oral liquid preparations such as syrups or elixirs are prepared by mixing the active compound and sweetening agents (e.g. sucrose), preservatives (e.g. methylparaben, propylparaben), colorants, flavors, and the like. The preparations for parenteral administration may also be prepared by a conventional method, for example, by dissolving the compound (I) of the present invention in a sterilized aqueous carrier, preferably water or a saline solution. Preferred liquid preparation suitable for parenteral administration is prepared by dissolving about 50-100 mg of the active compound (I) in water and an organic solvent and further in a polyethylene glycol having a molecular weight of 300 to 5000, which is preferably incorporated with a lubricant such as sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone, and polyvinyl alcohol. The above liquid preparations may preferably be further incorporated with a disinfectant (e.g. benzyl, alcohol, phenol, thimerosal), a fungicide, and further optionally with an isotonic agent (e.g. sucrose, sodium chloride), a topical anesthetic, a stabilizer, a buffer, and the like. In view of keeping stability, the preparation for parenteral administration may be filled in a capsule, followed by removing the aqueous medium by a conventional lyophilizing technique, and is recovered into a liquid preparation by dissolving in an aqueous medium when used.</p>
    <heading>EXAMPLES</heading> <p>The present invention is illustrated by the following preparation examples and experiments of active oxygen scavenging activity of the compounds, but should not be construed to be limited thereto.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Preparation 1</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="4"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="42pt" align="right"> </colspec> <colspec colname="3" colwidth="28pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">6-[4-(1-Cyclohexyl-1,2,3,4-tetrazol-5-</td>
                <td class="description-td">5</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">yl)butoxy]-3,4-dihydrocarbostyril</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Polyethyleneglycol (molecular weight: 4000)</td>
                <td class="description-td">0.3</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Sodium chloride</td>
                <td class="description-td">0.9</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Polyoxyethylene sorbitan monooleate</td>
                <td class="description-td">0.4</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Sodium metabisulfite</td>
                <td class="description-td">0.1</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Methylparaben</td>
                <td class="description-td">0.18</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Propylparaben</td>
                <td class="description-td">0.02</td>
                <td class="description-td">g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Distilled water for injection</td>
                <td class="description-td">10.0</td>
                <td class="description-td">ml</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>The above parabens, sodium metabisulfite and sodium chloride are dissolved in a half amount of the above distilled water with stirring at 80° C. The mixture is cooled to 40° C., and thereto are dissolved the active compound, and further polyethylene glycol and polyoxyethylene sorbitan monooleate. The remaining distilled water for injection is added to the mixture, sterilized by filtering with a filter paper to give the desired injection preparation.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Preparation 2</td>
              </tr> <tr class="description-tr"> <td class="description-td">Preparation of tablets:</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="147pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Components</td>
                <td class="description-td">Amount (g)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="147pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">6-[4-(1-Cyclohexyl-1,2,3,4-tetrazol-5-</td>
                <td class="description-td">100</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">yl)butoxy]-3,4-dihydrocarbostyril</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Lactose (Japanese Pharmacopeia)</td>
                <td class="description-td">40</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Cornstarch (Japanese Pharmacopeia)</td>
                <td class="description-td">40</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Crystalline cellulose (Japanese Pharmacopeia)</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Hydroxypropylcellulose (Japanese Pharmacopeia)</td>
                <td class="description-td">4</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Magnesium stearate (Japanese Pharmacopeia)</td>
                <td class="description-td">2</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>The above compound of the present invention, lactose, cornstarch and crystalline cellulose are mixed well and the mixture is granulated with 5% aqueous solution of hydroxypropylcellulose, and the granulated mixture is sieved with 200 mesh screen to dry the granules carefully, and then the granules are tabletted by a conventional method to give tablets (1000 tablets).</p>
    <heading>Pharmacological Experiments</heading> <p>The active oxygen scavenging effects of the representative compound of the present invention: cilostazol were tested</p>
    <heading>Experiment 1</heading> <p>Hydroxyl radical scavenging efficacy of cilostazol:</p>
    <p>Hydroxyl radical scavenging efficacy of cilostazol was determined in air-saturated phosphate buffer (10 mM) at room temperature. The reaction was initiated by addition of a small aliquot (5 μL) of Fe<sup>2+</sup> solution (10 mM FeSO<sub>4 </sub>in 10 mM HCl) to a buffer containing cilostazol, H<sub>2</sub>O<sub>2 </sub>(0.12 mM) and 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) (1 mM). The sample was transferred quickly to flat quartz electron paramagnetic resonance (EPR) cell, and measurements were started immediately.</p>
    <p>The EPR spectra of the spin-adduct of DMPO with the hydroxyl radical: DMPO/.OH was observed when DMPO reacted with hydroxyl radical generated by the Fenton system. The EPR spectra (.OH) are shown in the accompanying FIG. <b>1</b>. Scavenging of hydroxyl radicals was confirmed by using catalase (0.510 U/ml) (data not shown).</p>
    <p>As is seen from FIG. 1, cilostazol potently inhibited the DMPO/.OH adduct formation in a concentration-dependent manner. The signals were almost ameliorated at 10<sup>−5 </sup>M of cilostazol, suggestive of strong scavenger of hydroxyl radicals. The concentration required for inhibiting hydroxyl radical formation (IC<sub>50</sub>) was 2.58±0.07 μM.</p>
    <heading>Experiment 2</heading> <p>Peroxyl radical absorbing capacity (PRAC) assay:</p>
    <p>According to the method described by Cao et al. (Cao G, Alessio HM, Cutler RG (1993), Oxygen-radical absorbance capacity assay for antioxidants, Free Radic. Biol. Med 14: 303-311), the assay is based on production of peroxyl radicals by 2,2′-azobis(2-amidinopropane) hydrochloride (3 mM), a peroxyl radical generator, with subsequent oxidation of the reporter protein, β-phycoerythrin (16.7 nM) in 24 well plates. Into each sample well, either 20 μl of phosphate buffer or 20 μl of each concentration of cilostazol was included. After adding 2,2′-azobis(2-amidinopropane) hydrochloride, the reaction mixture was incubated at 37° C. Loss of fluorescence was measured every 5 minutes at the emission of 590 nm and excitation of 485 nm using Fluorescence Plate Reader (Bio-Tek Instruments, Inc., Winooski, USA). The PRAC value of the compound is reflected in the increase of area under curve of fluorescence versus time. Trolox was used as a reference for PRAC assay. The fluorescence just prior to addition of the 2,2′-azobis(2-amidinopropane) hydrochloride was estimated as the 100% value for that sample. The PRAC values were calculated by the following equation: <maths> <math> <mrow> <mstyle> <mtext>PRAC</mtext> </mstyle> <mo>=</mo> <mfrac> <mrow> <mstyle> <mtext>[Area  of  compound</mtext> </mstyle> <mo>-</mo> <mstyle> <mtext>Area  of  blank]</mtext> </mstyle> </mrow> <mrow> <mstyle> <mtext>[Area  of  1  µM  trolox</mtext> </mstyle> <mo>-</mo> <mstyle> <mtext>Area  of  blank]</mtext> </mstyle> </mrow> </mfrac> </mrow> </math> <div class="patent-image small-patent-image"> <a href="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-M00001.png"> <img id="EMI-M00001" file="US06743806-20040601-M00001.TIF" img-content="math" img-format="tif" alt="Figure US06743806-20040601-M00001" src="//patentimages.storage.googleapis.com/US6743806B2/US06743806-20040601-M00001.png" class="patent-full-image"> </a> </div> <attachments> <attachment idref="MATHEMATICA-00001" attachment-type="nb" file="US06743806-20040601-M00001.NB"> </attachment> </attachments> </maths> </p>
    <p>where 1 PRAC unit is the value of 1 μM of trolox.</p>
    <p>The time-dependent decrease of β-phycoerythrin fluorescence in the absence (blank) and the presence of different concentrations of cilostazol is shown, in the accompanying FIG. <b>2</b>. As is shown in FIG. 2, the β-phycoerythrin is characterized by its ability toil rapidly lose its fluorescence when exposed to a source, of free radicals. The decrease in the β-phycoerythrin fluorescense showed a delay time dependency, on the concentration of the antioxidants for time length of 125 minutes. In the presence of 10<sup>−6 and </sup>10<sup>−4 </sup>M of cilostazol, there was a right shift of the extinction curve, suggestive of its scavenging effect. The PRAC values (unit) calculated for cilostazol (10<sup>−6 </sup>and 10<sup>−4 </sup>M) were 1.325 and 1.938, respectively.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4277479">US4277479</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 1979</td><td class="patent-data-table-td patent-date-value">Jul 7, 1981</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Anti-asthmatic, hypotensive, anti-ulcer, antiinflammatory, vasodilation, enzyme inhibitors, anticoagulants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=9aVmBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DS5649378A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNGEcC_jRRsTjK41tPMBlcQIz3rIUg">JPS5649378A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jae Moon Choi et al., "<a href='http://scholar.google.com/scholar?q="Neuroprotective+Effect+of+Cilostazol+Against+Focal+Cerbral+Ischemia+via+Antipoptotic+Action+in+Rats%2C"'>Neuroprotective Effect of Cilostazol Against Focal Cerbral Ischemia via Antipoptotic Action in Rats,</a>" The Journal of Pharmacology and Experimental Therapeutics, vol. 300, No. 3, pp. 787-793, (2002).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Koizumi et al., :Changes in platelet aggregability, etc. CA 132:1611050, dtd. 2000.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee et al., "<a href='http://scholar.google.com/scholar?q="Neuroprotective+Effect+of+Cilostazol+Against+Focal+Ischemic+Brain+Damage%2C"'>Neuroprotective Effect of Cilostazol Against Focal Ischemic Brain Damage,</a>" Program &amp; Abstracts, The Korean Society of Pharmacology, p. 148, P 016, (11/5/01).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee et al., "<a href='http://scholar.google.com/scholar?q="Neuroprotective+Effect+of+Cilostazol+Against+Focal+Ischemic+Brain+Damage%2C"'>Neuroprotective Effect of Cilostazol Against Focal Ischemic Brain Damage,</a>" The Korean Journal of Physiology &amp; Pharmacology, vol. 5., No. 6, Supplement, P-016, (12/01).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nagai, "<a href='http://scholar.google.com/scholar?q="TNF-.alpha.+formation+inhibitors%2C+etc."'>TNF-.alpha. formation inhibitors, etc.</a>" CA 129:76497, dtd. 1998.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nishi et al. IV, "<a href='http://scholar.google.com/scholar?q="Research+and+development%2C+etc."'>Research and development, etc.</a>" CA 134:187764, dtd. 2001.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nishi et al.., "<a href='http://scholar.google.com/scholar?q="Studies+on+2-oxoquinoline%2C+etc."'>Studies on 2-oxoquinoline, etc.</a>" CA 99:98806, dtd. 1983.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Oishi et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+cilostazol%2C+etc."'>Effect of cilostazol, etc.</a>" CA 133:12525, dated 2000.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Otsuka, Carbostyril derivatives, etc., CA 95:126250, dtd, 1981.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shinoda-Tagawa et al., "<a href='http://scholar.google.com/scholar?q="A+phosphodiesterase+inhibitor%2C+etc."'>A phosphodiesterase inhibitor, etc.</a>" CA 137:288846, dtd. 2002.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Watanabe et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+cilostazol+on%2C+etc."'>Effect of cilostazol on, etc.</a>" CA 105:91040, dtd. 1986.</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7825130">US7825130</a></td><td class="patent-data-table-td patent-date-value">Feb 24, 2004</td><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Phosphatase and Tensin homolog deleted on chromosome Ten (PTEN), a tumor suppressor gene or calcium sensitive potassium channel modulators, comprising tetrazolylalkoxy-dihydrocarbostyril compounds such as Cilostazol , used for the treatment of Alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329731">US8329731</a></td><td class="patent-data-table-td patent-date-value">Dec 30, 2009</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">PTEN inhibitor or Maxi-K channels opener</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8580818">US8580818</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 14, 2006</td><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8653104">US8653104</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2012</td><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">PTEN inhibitor or Maxi-K channels opener</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2275106A1?cl=en">EP2275106A1</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2006</td><td class="patent-data-table-td patent-date-value">Jan 19, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007032557A1?cl=en">WO2007032557A1</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2006</td><td class="patent-data-table-td patent-date-value">Mar 22, 2007</td><td class="patent-data-table-td ">Otsuka Pharma Co Ltd</td><td class="patent-data-table-td ">Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S312000">514/312</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0401120000">C07D401/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031470900">A61K31/4709</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D401/12">C07D401/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=9aVmBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/4709">A61K31/4709</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/4709</span>, <span class="nested-value">C07D401/12</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jul 24, 2012</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120601</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 1, 2012</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 16, 2012</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 14, 2008</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 10, 2007</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 3, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 19, 2005</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050603</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1EbDtORLuOZmOTiGc-EEaunBXLpQ\u0026id=9aVmBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3W1bbwe4Mv8S25er6igc0IZViiyg\u0026id=9aVmBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1xgSIK2uCZK59GtrqI1CxVWM2Pmg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Tetrazolylalkoxy_dihydrocarbostyril_comp.pdf?id=9aVmBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3J8tJULl_vTGvrej10BM_p1F10NA"},"sample_url":"http://www.google.com/patents/reader?id=9aVmBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>